MedTrace Logo

The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

NCT05166837 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-12-20

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, single-ascending dose Phase Ⅰa study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects

Conditions

  • Healthy

Interventions

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

DRUG

STSA-1002 injection

Intravenous injection

DRUG

Placebo

Intravenous injection

Sponsors & Collaborators

  • Staidson (Beijing) Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-10
Primary Completion
2023-01-12
Completion
2023-01-12

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05166837 on ClinicalTrials.gov